BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhang Y, Huang S, Gong D, Qin Y, Shen Q. Programmed death-1 upregulation is correlated with dysfunction of tumor-infiltrating CD8+ T lymphocytes in human non-small cell lung cancer. Cell Mol Immunol 2010;7:389-95. [PMID: 20514052 DOI: 10.1038/cmi.2010.28] [Cited by in Crossref: 177] [Cited by in F6Publishing: 199] [Article Influence: 13.6] [Reference Citation Analysis]
Number Citing Articles
1 Engin A, Turna A, Esen F, Agkoc M, Cikman DI, Saglam OF, Deniz G, Aktas EC. Mediastinal lymph node removal ameliorates cytotoxic T-lymphocyte functions in patients with non-small cell lung cancer. Tumori 2023;109:97-104. [PMID: 34918599 DOI: 10.1177/03008916211064643] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Qiu D, Xi H, Wang M, Jing P, Ren Z, Chang N, Jiang W, Yang X, Zhang Y, Chen X, Zhang Y, Zhang J. The debatable role of immune checkpoint blockade therapy in lung adenocarcinoma-oriented liver metastatic malignant lesions. J Cancer Res Clin Oncol 2022. [PMID: 36583744 DOI: 10.1007/s00432-022-04538-5] [Reference Citation Analysis]
3 Rajasekaran K, Guan X, Tafazzol A, Hamidi H, Darwish M, Yadav M. Tetramer-aided sorting and single-cell RNA sequencing facilitate transcriptional profiling of antigen-specific CD8+ T cells. Transl Oncol 2022;27:101559. [PMID: 36279715 DOI: 10.1016/j.tranon.2022.101559] [Reference Citation Analysis]
4 Altaf R, Jadoon SS, Muhammad SA, Ilyas U, Duan Y. Recent advances in immune checkpoint inhibitors for non-small lung cancer treatment. Front Oncol 2022;12:1014156. [DOI: 10.3389/fonc.2022.1014156] [Reference Citation Analysis]
5 Ullah A, Pulliam S, Karki NR, Khan J, Jogezai S, Sultan S, Muhammad L, Khan M, Jamil N, Waheed A, Belakhlef S, Ghleilib I, Vail E, Heneidi S, Karim NA. PD-L1 Over-Expression Varies in Different Subtypes of Lung Cancer: Will This Affect Future Therapies? Clinics and Practice 2022;12:653-671. [DOI: 10.3390/clinpract12050068] [Reference Citation Analysis]
6 Gannichida A, Nakazawa Y, Kageyama A, Utsumi H, Kuwano K, Kawakubo T. Necessity of neutrophil-to-lymphocyte ratio monitoring for hypothyroidism using nivolumab in patients with cancer. World J Clin Oncol 2022; 13(7): 641-651 [DOI: 10.5306/wjco.v13.i7.641] [Reference Citation Analysis]
7 Del Bello A, Gouin A, Chaubet C, Kamar N, Treiner E. The CD226/TIGIT axis is involved in T cell hypo-responsiveness appearance in long-term kidney transplant recipients. Sci Rep 2022;12:11821. [PMID: 35821240 DOI: 10.1038/s41598-022-15705-6] [Reference Citation Analysis]
8 Shen DD, Bi YP, Pang JR, Zhao LJ, Zhao LF, Gao Y, Wang B, Liu HM, Liu Y, Wang N, Zheng YC, Liu HM. Generation, secretion and degradation of cancer immunotherapy target PD-L1. Cell Mol Life Sci 2022;79:413. [PMID: 35819633 DOI: 10.1007/s00018-022-04431-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Nowroozi A, Khalili N, Razi S, Keshavarz-Fathi M, Rezaei N. Tumor-infiltrating lymphocyte therapy for lung cancer and its future paradigms. Expert Opin Biol Ther 2022. [PMID: 35477305 DOI: 10.1080/14712598.2022.2072206] [Reference Citation Analysis]
10 Titov A, Kaminskiy Y, Ganeeva I, Zmievskaya E, Valiullina A, Rakhmatullina A, Petukhov A, Miftakhova R, Rizvanov A, Bulatov E. Knowns and Unknowns about CAR-T Cell Dysfunction. Cancers (Basel) 2022;14:1078. [PMID: 35205827 DOI: 10.3390/cancers14041078] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
11 Bian J, Niu Y, Ma Y, Chen F, Ma N, Algalil FA. A Review on the Application of PD-1 Blockade in EBV-Associated Nasopharyngeal Carcinoma Immunotherapy. Applied Bionics and Biomechanics 2022;2022:1-6. [DOI: 10.1155/2022/8537966] [Reference Citation Analysis]
12 Kim J, Jang H, Lee GJ, Hur Y, Keum J, Jo JK, Yun SE, Park SJ, Park YJ, Choi MJ, Kim KS, Kim J. A Novel Kinase Inhibitor AX-0085 Inhibits Interferon-γ-Mediated Induction of PD-L1 Expression and Promotes Immune Reaction to Lung Adenocarcinoma Cells. Cells 2021;11:19. [PMID: 35011581 DOI: 10.3390/cells11010019] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
13 Liu Z, Wen J, Hu F, Wang J, Hu C, Zhang W. Thrombospondin-1 induced programmed death-ligand 1-mediated immunosuppression by activating the STAT3 pathway in osteosarcoma. Cancer Sci 2021. [PMID: 34927311 DOI: 10.1111/cas.15237] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Palicelli A, Bonacini M, Croci S, Magi-Galluzzi C, Cañete-Portillo S, Chaux A, Bisagni A, Zanetti E, De Biase D, Melli B, Sanguedolce F, Zanelli M, Bonasoni MP, De Marco L, Soriano A, Ascani S, Zizzo M, Castro Ruiz C, De Leo A, Giordano G, Landriscina M, Carrieri G, Cormio L, Berney DM, Gandhi J, Santandrea G, Gelli MC, Tafuni A, Ragazzi M. What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 2: Clinic-Pathologic Correlations. Cells 2021;10:3165. [PMID: 34831388 DOI: 10.3390/cells10113165] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
15 Wang R, Singaraju A, Marks KE, Shakib L, Dunlap G, Cunningham-bussel A, Chen L, Tirpack A, Fein MR, Todd DJ, Macfarlane L, Goodman SM, Dicarlo EF, Massarotti EM, Sparks JA, Hamnvik OR, Min L, Jonsson AH, Brenner MB, Chan KK, Bass AR, Donlin LT, Rao DA. Clonally expanded CD38hi cytotoxic CD8 T cells define the T cell infiltrate in checkpoint inhibitor-associated arthritis.. [DOI: 10.1101/2021.10.19.464961] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
16 Yamaguchi A, Kawagoe I, Inoue S, Kochiyama T, Fukuda M, Saito M, Hayashida M. Propofol decreases CD8+ T cells and sevoflurane increases regulatory T cells after lung cancer resection: a randomized controlled trial. J Thorac Dis 2021;13:5430-8. [PMID: 34659809 DOI: 10.21037/jtd-21-878] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
17 Capitani N, Patrussi L, Baldari CT. Nature vs. Nurture: The Two Opposing Behaviors of Cytotoxic T Lymphocytes in the Tumor Microenvironment. Int J Mol Sci 2021;22:11221. [PMID: 34681881 DOI: 10.3390/ijms222011221] [Reference Citation Analysis]
18 DiNatale RG, Hakimi AA, Chan TA. Genomics-based immuno-oncology: bridging the gap between immunology and tumor biology. Hum Mol Genet 2020;29:R214-25. [PMID: 33029628 DOI: 10.1093/hmg/ddaa203] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
19 Nie D, Xue Y, Fang Q, Cheng J, Li B, Wang D, Li C, Gui S, Zhang Y, Zhao P. Immune Checkpoints: Therapeutic Targets for Pituitary Tumors. Dis Markers 2021;2021:5300381. [PMID: 34447484 DOI: 10.1155/2021/5300381] [Reference Citation Analysis]
20 Beumer-Chuwonpad A, Taggenbrock RLRE, Ngo TA, van Gisbergen KPJM. The Potential of Tissue-Resident Memory T Cells for Adoptive Immunotherapy against Cancer. Cells 2021;10:2234. [PMID: 34571883 DOI: 10.3390/cells10092234] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
21 Bozinovski S, Vannitamby A, Rangamuwa K, Aujla S, Wang H, Aloe C, Irving L, Leong TT, Steinfort DP. Integrating endobronchial ultrasound bronchoscopy with molecular testing of immunotherapy biomarkers in non-small cell lung cancer. Transl Lung Cancer Res 2021;10:2779-87. [PMID: 34295677 DOI: 10.21037/tlcr-20-781] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
22 Zhou X, Li Y, Ji Y, Liu T, Zhao N, He J, Yao J. PD-1 Involvement in Peripheral Blood CD8+ T Lymphocyte Dysfunction in Patients with Acute-on-chronic Liver Failure. J Clin Transl Hepatol 2021;9:283-90. [PMID: 34221914 DOI: 10.14218/JCTH.2020.00142] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
23 Cheng H, Ma K, Zhang L, Li G. The tumor microenvironment shapes the molecular characteristics of exhausted CD8+ T cells. Cancer Lett 2021;506:55-66. [PMID: 33662493 DOI: 10.1016/j.canlet.2021.02.013] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
24 Guo J, Mu D, Han Y. [Research Progress on the Mechanism and Clinical Data of Cereblon 
in Reversing the Resistance of Lung Cancer to PD-1 Antibody by T cells]. Zhongguo Fei Ai Za Zhi 2021;24:49-55. [PMID: 33478191 DOI: 10.3779/j.issn.1009-3419.2020.102.49] [Reference Citation Analysis]
25 Saka H, Nishio M, Hida T, Nakagawa K, Sakai H, Nogami N, Atagi S, Takahashi T, Horinouchi H, Takenoyama M, Katakami N, Tanaka H, Takeda K, Satouchi M, Isobe H, Maemondo M, Goto K, Hirashima T, Minato K, Yada N, Tamura T. Five-year follow-up results from phase II studies of nivolumab in Japanese patients with previously treated advanced non-small cell lung cancer: pooled analysis of the ONO-4538-05 and ONO-4538-06 studies. Jpn J Clin Oncol 2021;51:106-13. [PMID: 33020837 DOI: 10.1093/jjco/hyaa157] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
26 Ahluwalia P, Ahluwalia M, Mondal AK, Sahajpal N, Kota V, Rojiani MV, Rojiani AM, Kolhe R. Immunogenomic Gene Signature of Cell-Death Associated Genes with Prognostic Implications in Lung Cancer. Cancers (Basel) 2021;13:E155. [PMID: 33466402 DOI: 10.3390/cancers13010155] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 7.5] [Reference Citation Analysis]
27 Myers JW, Peoples GE, Clifton GT. Overcoming Cancer Tolerance with Immune Checkpoint Blockade. Cancer Immunology 2021. [DOI: 10.1007/978-3-030-50287-4_6] [Reference Citation Analysis]
28 Zuazo M, Arasanz H, Bocanegra A, Fernandez G, Chocarro L, Vera R, Kochan G, Escors D. Systemic CD4 Immunity as a Key Contributor to PD-L1/PD-1 Blockade Immunotherapy Efficacy. Front Immunol 2020;11:586907. [PMID: 33329566 DOI: 10.3389/fimmu.2020.586907] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
29 Li Z, Li B, Li L, Wang G, Li Y, Fu R, Ming Y, Ni R, Wang J, Ye G, Chen J. The Immunostimulative Effect and Mechanisms of a Novel Mouse Anti-Human PD-1 Monoclonal Antibody on Jurkat Lymphocytic Cells Cocultured with Hepatoma Cells. Onco Targets Ther 2020;13:12225-41. [PMID: 33273828 DOI: 10.2147/OTT.S281397] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
30 Galgani M, Bruzzaniti S, La Rocca C, Micillo T, de Candia P, Bifulco M, Matarese G. Immunometabolism of regulatory T cells in cancer. Mol Aspects Med 2021;77:100936. [PMID: 33250195 DOI: 10.1016/j.mam.2020.100936] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
31 Kanev K, Zehn D. Origin and fine-tuning of effector CD8 T cell subpopulations in chronic infection. Curr Opin Virol 2021;46:27-35. [PMID: 33137688 DOI: 10.1016/j.coviro.2020.10.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
32 Zhang Q, Zhou K, Liang W, Xiong W. Prognostic and clinicopathological significance of PD-1 expression in hepatocellular carcinoma: a meta-analysis. J Int Med Res 2020;48:300060520962675. [PMID: 33100077 DOI: 10.1177/0300060520962675] [Reference Citation Analysis]
33 Pawłowska A, Suszczyk D, Tarkowski R, Paduch R, Kotarski J, Wertel I. Programmed Death-1 Receptor (PD-1) as a Potential Prognosis Biomarker for Ovarian Cancer Patients. Cancer Manag Res 2020;12:9691-709. [PMID: 33116828 DOI: 10.2147/CMAR.S263010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
34 Manfredi F, Cianciotti BC, Potenza A, Tassi E, Noviello M, Biondi A, Ciceri F, Bonini C, Ruggiero E. TCR Redirected T Cells for Cancer Treatment: Achievements, Hurdles, and Goals. Front Immunol 2020;11:1689. [PMID: 33013822 DOI: 10.3389/fimmu.2020.01689] [Cited by in Crossref: 37] [Cited by in F6Publishing: 40] [Article Influence: 12.3] [Reference Citation Analysis]
35 Hong SA, Hwang HW, Kim MK, Lee TJ, Yim K, Won HS, Sun S, Kim EY, Ko YH. High Endothelial Venule with Concomitant High CD8+ Tumor-Infiltrating Lymphocytes Is Associated with a Favorable Prognosis in Resected Gastric Cancer. J Clin Med 2020;9:E2628. [PMID: 32823631 DOI: 10.3390/jcm9082628] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
36 Roessner PM, Seiffert M. T-cells in chronic lymphocytic leukemia: Guardians or drivers of disease? Leukemia 2020;34:2012-24. [PMID: 32457353 DOI: 10.1038/s41375-020-0873-2] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 14.0] [Reference Citation Analysis]
37 Kuai W, Xu X, Yan J, Zhao W, Li Y, Wang B, Yuan N, Li Z, Jia Y. Prognostic Impact of PD-1 and Tim-3 Expression in Tumor Tissue in Stage I-III Colorectal Cancer. Biomed Res Int 2020;2020:5294043. [PMID: 32509862 DOI: 10.1155/2020/5294043] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
38 Linsley PS, Long SA. Enforcing the checkpoints: harnessing T-cell exhaustion for therapy of T1D. Curr Opin Endocrinol Diabetes Obes 2019;26:213-8. [PMID: 31157632 DOI: 10.1097/MED.0000000000000488] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
39 Choi B, Lee JS, Kim SJ, Hong D, Park JB, Lee KY. Anti-tumor effects of anti-PD-1 antibody, pembrolizumab, in humanized NSG PDX mice xenografted with dedifferentiated liposarcoma. Cancer Lett 2020;478:56-69. [PMID: 32145342 DOI: 10.1016/j.canlet.2020.02.042] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
40 Outh-Gauer S, Morini A, Tartour E, Lépine C, Jung AC, Badoual C. The Microenvironment of Head and Neck Cancers: Papillomavirus Involvement and Potential Impact of Immunomodulatory Treatments. Head Neck Pathol 2020;14:330-40. [PMID: 32124416 DOI: 10.1007/s12105-020-01147-x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 6.3] [Reference Citation Analysis]
41 Im SJ, Ha SJ. Re-defining T-Cell Exhaustion: Subset, Function, and Regulation. Immune Netw 2020;20:e2. [PMID: 32158590 DOI: 10.4110/in.2020.20.e2] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 5.7] [Reference Citation Analysis]
42 Dora D, Rivard C, Yu H, Bunn P, Suda K, Ren S, Pickard SL, Laszlo V, Harko T, Megyesfalvi Z, Moldvay J, Hirsch FR, Dome B, Lohinai Z. Small Cell Lung Cancer Neuroendocrine Subtypes are Associated with Different Immune Microenvironment and Checkpoint Molecule Distribution.. [DOI: 10.1101/2020.02.02.930305] [Reference Citation Analysis]
43 Chen L, Cao MF, Xiao JF, Ma QH, Zhang H, Cai RL, Miao JY, Wang WY, Zhang H, Luo M, Ping YF, Yao XH, Cui YH, Zhang X, Bian XW. Stromal PD-1+ tumor-associated macrophages predict poor prognosis in lung adenocarcinoma. Hum Pathol 2020;97:68-79. [PMID: 31926212 DOI: 10.1016/j.humpath.2019.12.007] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
44 Prado-garcia H, Romero-garcia S. The Role of Exhaustion in Tumor-Induced T-Cell Dysfunction in Cancer. Cancer Immunology 2020. [DOI: 10.1007/978-3-030-30845-2_8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
45 Ikematsu Y, Tanaka K, Yanagihara T, Liu R, Inoue H, Yoneshima Y, Ota K, Iwama E, Takata S, Hata K, Takahata Y, Wataya H, Nakanishi Y, Okamoto I. Immune checkpoint protein and cytokine expression by T lymphocytes in pleural effusion of cancer patients receiving anti-PD-1 therapy. Lung Cancer 2019;138:58-64. [PMID: 31639551 DOI: 10.1016/j.lungcan.2019.10.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
46 Chen L, Cao MF, Zhang X, Dang WQ, Xiao JF, Liu Q, Tan YH, Tan YY, Xu YY, Xu SL, Yao XH, Cui YH, Zhang X, Bian XW. The landscape of immune microenvironment in lung adenocarcinoma and squamous cell carcinoma based on PD-L1 expression and tumor-infiltrating lymphocytes. Cancer Med 2019;8:7207-18. [PMID: 31605439 DOI: 10.1002/cam4.2580] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 5.5] [Reference Citation Analysis]
47 Hu X, Gu Y, Li D, Zhao S, Hua S, Jiang Y. Analyzing the percentage of different PD-1+ T cell subsets in peripheral blood and bronchoalveolar lavage fluid of small cell lung cancer patients: A prospective study. Clin Exp Pharmacol Physiol 2019;46:1074-83. [PMID: 31381177 DOI: 10.1111/1440-1681.13153] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
48 Kitano Y, Yamashita YI, Nakao Y, Itoyama R, Yusa T, Umezaki N, Tsukamoto M, Yamao T, Miyata T, Nakagawa S, Okabe H, Imai K, Chikamoto A, Ishiko T, Baba H. Clinical Significance of PD-L1 Expression in Both Cancer and Stroma Cells of Cholangiocarcinoma Patients. Ann Surg Oncol 2020;27:599-607. [PMID: 31407173 DOI: 10.1245/s10434-019-07701-4] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 5.3] [Reference Citation Analysis]
49 Prodinger C, Reichelt J, Bauer JW, Laimer M. Epidermolysis bullosa: Advances in research and treatment. Exp Dermatol 2019;28:1176-89. [PMID: 31140655 DOI: 10.1111/exd.13979] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 7.5] [Reference Citation Analysis]
50 Horinouchi H, Nishio M, Hida T, Nakagawa K, Sakai H, Nogami N, Atagi S, Takahashi T, Saka H, Takenoyama M, Katakami N, Tanaka H, Takeda K, Satouchi M, Isobe H, Maemondo M, Goto K, Hirashima T, Minato K, Sumiyoshi N, Tamura T. Three-year follow-up results from phase II studies of nivolumab in Japanese patients with previously treated advanced non-small cell lung cancer: Pooled analysis of ONO-4538-05 and ONO-4538-06 studies. Cancer Med 2019;8:5183-93. [PMID: 31353840 DOI: 10.1002/cam4.2411] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
51 Shergold AL, Millar R, Nibbs RJ. Understanding and overcoming the resistance of cancer to PD-1/PD-L1 blockade. Pharmacological Research 2019;145:104258. [DOI: 10.1016/j.phrs.2019.104258] [Cited by in Crossref: 62] [Cited by in F6Publishing: 68] [Article Influence: 15.5] [Reference Citation Analysis]
52 Wildeman ME, Shepard MJ, Oldfield EH, Lopes MBS. Central Nervous System Germinomas Express Programmed Death Ligand 1. J Neuropathol Exp Neurol 2018;77:312-6. [PMID: 29415126 DOI: 10.1093/jnen/nly008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
53 Sa H, Ma K, Gao Y, Wang D. [Predictive Value of Tumor Mutation Burden in Immunotherapy for Lung Cancer]. Zhongguo Fei Ai Za Zhi 2019;22:380-4. [PMID: 31196372 DOI: 10.3779/j.issn.1009-3419.2019.06.08] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
54 Haragan A, Field JK, Davies MPA, Escriu C, Gruver A, Gosney JR. Heterogeneity of PD-L1 expression in non-small cell lung cancer: Implications for specimen sampling in predicting treatment response. Lung Cancer 2019;134:79-84. [PMID: 31320000 DOI: 10.1016/j.lungcan.2019.06.005] [Cited by in Crossref: 57] [Cited by in F6Publishing: 54] [Article Influence: 14.3] [Reference Citation Analysis]
55 Chiu PL, Chang CH, Lin YL, Tsou PH, Li BR. Rapid and Safe Isolation of Human Peripheral Blood B and T Lymphocytes through Spiral Microfluidic Channels. Sci Rep 2019;9:8145. [PMID: 31148602 DOI: 10.1038/s41598-019-44677-3] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
56 Altorki NK, Markowitz GJ, Gao D, Port JL, Saxena A, Stiles B, McGraw T, Mittal V. The lung microenvironment: an important regulator of tumour growth and metastasis. Nat Rev Cancer 2019;19:9-31. [PMID: 30532012 DOI: 10.1038/s41568-018-0081-9] [Cited by in Crossref: 378] [Cited by in F6Publishing: 416] [Article Influence: 94.5] [Reference Citation Analysis]
57 Serrano-Del Valle A, Anel A, Naval J, Marzo I. Immunogenic Cell Death and Immunotherapy of Multiple Myeloma. Front Cell Dev Biol 2019;7:50. [PMID: 31041312 DOI: 10.3389/fcell.2019.00050] [Cited by in Crossref: 78] [Cited by in F6Publishing: 86] [Article Influence: 19.5] [Reference Citation Analysis]
58 Liu S, Han Z, Trivett AL, Lin H, Hannifin S, Yang, Oppenheim JJ. Cryptotanshinone has curative dual anti-proliferative and immunotherapeutic effects on mouse Lewis lung carcinoma. Cancer Immunol Immunother 2019;68:1059-71. [PMID: 30972427 DOI: 10.1007/s00262-019-02326-8] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 5.3] [Reference Citation Analysis]
59 Xu N, Huang L, Li X, Watanabe M, Li C, Xu A, Liu C, Li Q, Araki M, Wada K, Nasu Y, Huang P. The Novel Combination of Nitroxoline and PD-1 Blockade, Exerts a Potent Antitumor Effect in a Mouse Model of Prostate Cancer. Int J Biol Sci 2019;15:919-28. [PMID: 31182913 DOI: 10.7150/ijbs.32259] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
60 Kim SH, Go SI, Song DH, Park SW, Kim HR, Jang I, Kim JD, Lee JS, Lee GW. Prognostic impact of CD8 and programmed death-ligand 1 expression in patients with resectable non-small cell lung cancer. Br J Cancer 2019;120:547-54. [PMID: 30745585 DOI: 10.1038/s41416-019-0398-5] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
61 Maschmeyer G, De Greef J, Mellinghoff SC, Nosari A, Thiebaut-Bertrand A, Bergeron A, Franquet T, Blijlevens NMA, Maertens JA; European Conference on Infections in Leukemia (ECIL). Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European Conference on Infections in Leukemia (ECIL). Leukemia 2019;33:844-62. [PMID: 30700842 DOI: 10.1038/s41375-019-0388-x] [Cited by in Crossref: 97] [Cited by in F6Publishing: 103] [Article Influence: 24.3] [Reference Citation Analysis]
62 Abdel-Hakeem MS. Viruses Teaching Immunology: Role of LCMV Model and Human Viral Infections in Immunological Discoveries. Viruses 2019;11:E106. [PMID: 30691215 DOI: 10.3390/v11020106] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
63 Iga N, Otsuka A, Yamamoto Y, Nakashima C, Honda T, Kitoh A, Nakajima S, Egawa G, Nomura T, Dainichi T, Matsushita S, Tanizaki H, Yamamoto Y, Funakoshi T, Fujisawa Y, Fujimura T, Hata H, Ishida Y, Kabashima K. Accumulation of exhausted CD8+ T cells in extramammary Paget's disease. PLoS One 2019;14:e0211135. [PMID: 30682105 DOI: 10.1371/journal.pone.0211135] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
64 Kitz A, Singer E, Hafler D. Regulatory T Cells: From Discovery to Autoimmunity. Cold Spring Harb Perspect Med 2018;8:a029041. [PMID: 29311129 DOI: 10.1101/cshperspect.a029041] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 6.2] [Reference Citation Analysis]
65 Zhang X, Hu F, Li C, Zheng X, Zhang B, Wang H, Tao G, Xu J, Zhang Y, Han B. OCT4&SOX2-specific cytotoxic T lymphocytes plus programmed cell death protein 1 inhibitor presented with synergistic effect on killing lung cancer stem-like cells in vitro and treating drug-resistant lung cancer mice in vivo. J Cell Physiol 2019;234:6758-68. [PMID: 30382588 DOI: 10.1002/jcp.27423] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
66 Natarajan A, Mayer AT, Reeves RE, Nagamine CM, Gambhir SS. Development of Novel ImmunoPET Tracers to Image Human PD-1 Checkpoint Expression on Tumor-Infiltrating Lymphocytes in a Humanized Mouse Model. Mol Imaging Biol 2017;19:903-14. [PMID: 28247187 DOI: 10.1007/s11307-017-1060-3] [Cited by in Crossref: 68] [Cited by in F6Publishing: 76] [Article Influence: 13.6] [Reference Citation Analysis]
67 Broos K, Lecocq Q, Raes G, Devoogdt N, Keyaerts M, Breckpot K. Noninvasive imaging of the PD-1:PD-L1 immune checkpoint: Embracing nuclear medicine for the benefit of personalized immunotherapy. Theranostics 2018;8:3559-70. [PMID: 30026866 DOI: 10.7150/thno.24762] [Cited by in Crossref: 62] [Cited by in F6Publishing: 70] [Article Influence: 12.4] [Reference Citation Analysis]
68 Jan CI, Tsai WC, Harn HJ, Shyu WC, Liu MC, Lu HM, Chiu SC, Cho DY. Predictors of Response to Autologous Dendritic Cell Therapy in Glioblastoma Multiforme. Front Immunol 2018;9:727. [PMID: 29910795 DOI: 10.3389/fimmu.2018.00727] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 6.2] [Reference Citation Analysis]
69 DiDomenico J, Lamano JB, Oyon D, Li Y, Veliceasa D, Kaur G, Ampie L, Choy W, Lamano JB, Bloch O. The immune checkpoint protein PD-L1 induces and maintains regulatory T cells in glioblastoma. Oncoimmunology 2018;7:e1448329. [PMID: 29900065 DOI: 10.1080/2162402X.2018.1448329] [Cited by in Crossref: 61] [Cited by in F6Publishing: 50] [Article Influence: 12.2] [Reference Citation Analysis]
70 Tang Y, He Y, Shi L, Yang L, Wang J, Lian Y, Fan C, Zhang P, Guo C, Zhang S, Gong Z, Li X, Xiong F, Li X, Li Y, Li G, Xiong W, Zeng Z. Co-expression of AFAP1-AS1 and PD-1 predicts poor prognosis in nasopharyngeal carcinoma. Oncotarget 2017;8:39001-11. [PMID: 28380458 DOI: 10.18632/oncotarget.16545] [Cited by in Crossref: 70] [Cited by in F6Publishing: 88] [Article Influence: 14.0] [Reference Citation Analysis]
71 Li Z, Li B, Peng D, Xing H, Wang G, Li P, Wang J, Ye G, Chen J. Expression and clinical significance of PD-1 in hepatocellular carcinoma tissues detected by a novel mouse anti-human PD-1 monoclonal antibody. Int J Oncol. 2018;52:2079-2092. [PMID: 29620156 DOI: 10.3892/ijo.2018.4358] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
72 Tini P, Nardone V, Pastina P, Pirtoli L, Correale P, Giordano A. The effects of radiotherapy on the survival of patients with unresectable non-small cell lung cancer. Expert Rev Anticancer Ther 2018;18:593-602. [PMID: 29582686 DOI: 10.1080/14737140.2018.1458615] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
73 Outh-Gauer S, Alt M, Le Tourneau C, Augustin J, Broudin C, Gasne C, Denize T, Mirghani H, Fabre E, Ménard M, Scotte F, Tartour E, Badoual C. Immunotherapy in head and neck cancers: A new challenge for immunologists, pathologists and clinicians. Cancer Treat Rev 2018;65:54-64. [PMID: 29547766 DOI: 10.1016/j.ctrv.2018.02.008] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 7.6] [Reference Citation Analysis]
74 Domblides C, Antoine M, Hamard C, Rabbe N, Rodenas A, Vieira T, Crequit P, Cadranel J, Lavolé A, Wislez M. Nonsmall cell lung cancer from HIV-infected patients expressed programmed cell death-ligand 1 with marked inflammatory infiltrates. AIDS 2018;32:461-8. [PMID: 29194117 DOI: 10.1097/QAD.0000000000001713] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
75 Kiriu T, Yamamoto M, Nagano T, Hazama D, Sekiya R, Katsurada M, Tamura D, Tachihara M, Kobayashi K, Nishimura Y. The time-series behavior of neutrophil-to-lymphocyte ratio is useful as a predictive marker in non-small cell lung cancer. PLoS One 2018;13:e0193018. [PMID: 29447258 DOI: 10.1371/journal.pone.0193018] [Cited by in Crossref: 45] [Cited by in F6Publishing: 51] [Article Influence: 9.0] [Reference Citation Analysis]
76 He L, Wang J, Chang D, Lv D, Li H, Zhang H. Clinical value of Pro-GRP and T lymphocyte subpopulation for the assessment of immune functions of lung cancer patients after DC-CIK biological therapy. Exp Ther Med 2018;15:1580-5. [PMID: 29399130 DOI: 10.3892/etm.2017.5520] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
77 Teng F, Meng X, Wang X, Yuan J, Liu S, Mu D, Zhu H, Kong L, Yu J. Expressions of CD8+TILs, PD-L1 and Foxp3+TILs in stage I NSCLC guiding adjuvant chemotherapy decisions. Oncotarget 2016;7:64318-29. [PMID: 27602763 DOI: 10.18632/oncotarget.11793] [Cited by in Crossref: 23] [Cited by in F6Publishing: 29] [Article Influence: 4.6] [Reference Citation Analysis]
78 Abdin SM, Zaher DM, Arafa EA, Omar HA. Tackling Cancer Resistance by Immunotherapy: Updated Clinical Impact and Safety of PD-1/PD-L1 Inhibitors. Cancers (Basel). 2018;10. [PMID: 29370105 DOI: 10.3390/cancers10020032] [Cited by in Crossref: 39] [Cited by in F6Publishing: 41] [Article Influence: 7.8] [Reference Citation Analysis]
79 Thomas A, Brahmer JR, Giaccone G. Humoral and Cellular Immune Dysregulation and Lung Cancer. IASLC Thoracic Oncology 2018. [DOI: 10.1016/b978-0-323-52357-8.00016-0] [Reference Citation Analysis]
80 Calabrò L, Rossi G, Maio M. New horizons from immunotherapy in malignant pleural mesothelioma. J Thorac Dis 2018;10:S322-32. [PMID: 29507802 DOI: 10.21037/jtd.2017.12.88] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
81 Dozier J, Chintala N, Adusumilli P. Immunotherapy for thoracic malignancies. Indian J Thorac Cardiovasc Surg 2018;34:54-64. [DOI: 10.1007/s12055-017-0566-2] [Reference Citation Analysis]
82 Wilson RAM, Evans TRJ, Fraser AR, Nibbs RJB. Immune checkpoint inhibitors: new strategies to checkmate cancer. Clin Exp Immunol. 2018;191:133-148. [PMID: 29139554 DOI: 10.1111/cei.13081] [Cited by in Crossref: 44] [Cited by in F6Publishing: 45] [Article Influence: 7.3] [Reference Citation Analysis]
83 Filippis C, Arens K, Noubissi Nzeteu GA, Reichmann G, Waibler Z, Crauwels P, van Zandbergen G. Nivolumab Enhances In Vitro Effector Functions of PD-1+ T-Lymphocytes and Leishmania-Infected Human Myeloid Cells in a Host Cell-Dependent Manner. Front Immunol 2017;8:1880. [PMID: 29312350 DOI: 10.3389/fimmu.2017.01880] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
84 Zhao YJ, Sun WP, Peng JH, Deng YX, Fang YJ, Huang J, Zhang HZ, Wan DS, Lin JZ, Pan ZZ. Programmed death-ligand 1 expression correlates with diminished CD8+ T cell infiltration and predicts poor prognosis in anal squamous cell carcinoma patients. Cancer Manag Res 2018;10:1-11. [PMID: 29296096 DOI: 10.2147/CMAR.S153965] [Cited by in Crossref: 15] [Cited by in F6Publishing: 20] [Article Influence: 2.5] [Reference Citation Analysis]
85 Simon S, Vignard V, Varey E, Parrot T, Knol A, Khammari A, Gervois N, Lang F, Dreno B, Labarriere N. Emergence of High-Avidity Melan-A–Specific Clonotypes as a Reflection of Anti–PD-1 Clinical Efficacy. Cancer Research 2017;77:7083-7093. [DOI: 10.1158/0008-5472.can-17-1856] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
86 Chen Y, Li Q, Li X, Ma D, Fang J, Luo L, Liu X, Wang X, Lui VWY, Xia J, Cheng B, Wang Z. Blockade of PD-1 effectively inhibits in vivo malignant transformation of oral mucosa. Oncoimmunology 2018;7:e1388484. [PMID: 29308315 DOI: 10.1080/2162402X.2017.1388484] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
87 Cho JH, Oezkan F, Koenig M, Otterson GA, Herman JG, He K. Epigenetic Therapeutics and Their Impact in Immunotherapy of Lung Cancer. Curr Pharmacol Rep 2017;3:360-73. [DOI: 10.1007/s40495-017-0110-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
88 Filley AC, Henriquez M, Dey M. Recurrent glioma clinical trial, CheckMate-143: the game is not over yet. Oncotarget 2017;8:91779-94. [PMID: 29207684 DOI: 10.18632/oncotarget.21586] [Cited by in Crossref: 227] [Cited by in F6Publishing: 248] [Article Influence: 37.8] [Reference Citation Analysis]
89 Wankowicz SA, Werner L, Orsola A, Novak J, Bowden M, Choueiri TK, de Torres I, Morote J, Freeman GJ, Signoretti S, Bellmunt J. Differential Expression of PD-L1 in High Grade T1 vs Muscle Invasive Bladder Carcinoma and its Prognostic Implications. Journal of Urology 2017;198:817-23. [DOI: 10.1016/j.juro.2017.04.102] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.2] [Reference Citation Analysis]
90 Okoye IS, Houghton M, Tyrrell L, Barakat K, Elahi S. Coinhibitory Receptor Expression and Immune Checkpoint Blockade: Maintaining a Balance in CD8+ T Cell Responses to Chronic Viral Infections and Cancer. Front Immunol. 2017;8:1215. [PMID: 29033936 DOI: 10.3389/fimmu.2017.01215] [Cited by in Crossref: 57] [Cited by in F6Publishing: 58] [Article Influence: 9.5] [Reference Citation Analysis]
91 Zhang P, Bao Z, Xu L, Zhou J, Lu G, Yao Y, Liu R, Gao Q, Shen Y, Zhou J. PD-L1 expression indicates favorable prognosis for advanced lung adenocarcinoma patients treated with pemetrexed. Oncotarget 2017;8:66293-304. [PMID: 29029512 DOI: 10.18632/oncotarget.19973] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
92 Goods BA, Hernandez AL, Lowther DE, Lucca LE, Lerner BA, Gunel M, Raddassi K, Coric V, Hafler DA, Love JC. Functional differences between PD-1+ and PD-1- CD4+ effector T cells in healthy donors and patients with glioblastoma multiforme. PLoS One 2017;12:e0181538. [PMID: 28880903 DOI: 10.1371/journal.pone.0181538] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 5.0] [Reference Citation Analysis]
93 Zhang P, Bao Z, Xu L, Zhou J, Lu G, Yao Y, Liu R, Gao Q, Shen Y, Zhou J. PD-L1 expression indicates favorable prognosis for advanced lung adenocarcinoma patients treated with pemetrexed. Oncotarget 2017;8:66293-304. [PMID: 29029512 DOI: 10.18632/oncotarget.19973] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
94 Wang J, Jia Y, Zhao S, Zhang X, Wang X, Han X, Wang Y, Ma M, Shi J, Liu L. BIN1 reverses PD-L1-mediated immune escape by inactivating the c-MYC and EGFR/MAPK signaling pathways in non-small cell lung cancer. Oncogene 2017;36:6235-43. [PMID: 28714960 DOI: 10.1038/onc.2017.217] [Cited by in Crossref: 54] [Cited by in F6Publishing: 59] [Article Influence: 9.0] [Reference Citation Analysis]
95 Ishii H, Azuma K, Kawahara A, Matsuo N, Tokito T, Kinoshita T, Yamada K, Sasada T, Akiba J, Hoshino T. Programmed cell death-ligand 1 expression and immunoscore in stage II and III non-small cell lung cancer patients receiving adjuvant chemotherapy. Oncotarget 2017;8:61618-25. [PMID: 28977890 DOI: 10.18632/oncotarget.18651] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
96 Chang H, Kim JS, Choi YJ, Cho JG, Woo JS, Kim A, Kim JS, Kang EJ. Overexpression of PD-L2 is associated with shorter relapse-free survival in patients with malignant salivary gland tumors. Onco Targets Ther 2017;10:2983-92. [PMID: 28652780 DOI: 10.2147/OTT.S134589] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 5.8] [Reference Citation Analysis]
97 Fang W, Chen Y, Sheng J, Zhou T, Zhang Y, Zhan J, Liu L, Huang J, Peng P, Zhang L. Association between PD-L1 Expression on Tumour-Infiltrating Lymphocytes and Overall Survival in Patients with Gastric Cancer. J Cancer. 2017;8:1579-1585. [PMID: 28775777 DOI: 10.7150/jca.18729] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
98 Dozier J, Zheng H, Adusumilli PS. Immunotherapy for malignant pleural mesothelioma: current status and future directions. Transl Lung Cancer Res 2017;6:315-24. [PMID: 28713676 DOI: 10.21037/tlcr.2017.05.02] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 3.7] [Reference Citation Analysis]
99 Syed Khaja AS, Toor SM, El Salhat H, Ali BR, Elkord E. Intratumoral FoxP3+Helios+ Regulatory T Cells Upregulating Immunosuppressive Molecules Are Expanded in Human Colorectal Cancer. Front Immunol 2017;8:619. [PMID: 28603527 DOI: 10.3389/fimmu.2017.00619] [Cited by in Crossref: 57] [Cited by in F6Publishing: 59] [Article Influence: 9.5] [Reference Citation Analysis]
100 Wang F, Hou H, Zhou H, Wu S, Mao L, Huang M, Yin B, Huang J, Sun Z. Use of TBAg/PHA ratio in distinguishing tuberculoma from cancer in solitary pulmonary nodule or mass. Clin Respir J 2018;12:1174-81. [PMID: 28488310 DOI: 10.1111/crj.12648] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
101 Ma K, Wei X, Dong D, Wu Y, Geng Q, Li E. PD-L1 and PD-1 expression correlate with prognosis in extrahepatic cholangiocarcinoma. Oncol Lett. 2017;14:250-256. [PMID: 28693161 DOI: 10.3892/ol.2017.6105] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 4.7] [Reference Citation Analysis]
102 Ilcus C, Bagacean C, Tempescul A, Popescu C, Parvu A, Cenariu M, Bocsan C, Zdrenghea M. Immune checkpoint blockade: the role of PD-1-PD-L axis in lymphoid malignancies. Onco Targets Ther 2017;10:2349-63. [PMID: 28496333 DOI: 10.2147/OTT.S133385] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 4.7] [Reference Citation Analysis]
103 Hida T, Nishio M, Nogami N, Ohe Y, Nokihara H, Sakai H, Satouchi M, Nakagawa K, Takenoyama M, Isobe H, Fujita S, Tanaka H, Minato K, Takahashi T, Maemondo M, Takeda K, Saka H, Goto K, Atagi S, Hirashima T, Sumiyoshi N, Tamura T. Efficacy and safety of nivolumab in Japanese patients with advanced or recurrent squamous non-small cell lung cancer. Cancer Sci 2017;108:1000-6. [PMID: 28266091 DOI: 10.1111/cas.13225] [Cited by in Crossref: 42] [Cited by in F6Publishing: 50] [Article Influence: 7.0] [Reference Citation Analysis]
104 Dyck L, Mills KHG. Immune checkpoints and their inhibition in cancer and infectious diseases. Eur J Immunol. 2017;47:765-779. [PMID: 28393361 DOI: 10.1002/eji.201646875] [Cited by in Crossref: 295] [Cited by in F6Publishing: 310] [Article Influence: 49.2] [Reference Citation Analysis]
105 Prado-Garcia H, Romero-Garcia S, Puerto-Aquino A, Rumbo-Nava U. The PD-L1/PD-1 pathway promotes dysfunction, but not "exhaustion", in tumor-responding T cells from pleural effusions in lung cancer patients. Cancer Immunol Immunother 2017;66:765-76. [PMID: 28289860 DOI: 10.1007/s00262-017-1979-x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 4.2] [Reference Citation Analysis]
106 Nishio M, Hida T, Atagi S, Sakai H, Nakagawa K, Takahashi T, Nogami N, Saka H, Takenoyama M, Maemondo M, Ohe Y, Nokihara H, Hirashima T, Tanaka H, Fujita S, Takeda K, Goto K, Satouchi M, Isobe H, Minato K, Sumiyoshi N, Tamura T. Multicentre phase II study of nivolumab in Japanese patients with advanced or recurrent non-squamous non-small cell lung cancer. ESMO Open 2016;1:e000108. [PMID: 28861280 DOI: 10.1136/esmoopen-2016-000108] [Cited by in Crossref: 28] [Cited by in F6Publishing: 50] [Article Influence: 4.7] [Reference Citation Analysis]
107 Granier C, Soumelis V, Mandavit M, Gibault L, Belazzoug R, de Guillebon E, Badoual C, Tartour E, Roussel H. Les « immune checkpoints », comment ça marche. Annales de Pathologie 2017;37:18-28. [DOI: 10.1016/j.annpat.2016.12.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
108 Coy J, Caldwell A, Chow L, Guth A, Dow S. PD-1 expression by canine T cells and functional effects of PD-1 blockade. Vet Comp Oncol 2017;15:1487-502. [PMID: 28120417 DOI: 10.1111/vco.12294] [Cited by in Crossref: 36] [Cited by in F6Publishing: 39] [Article Influence: 6.0] [Reference Citation Analysis]
109 Okabe M, Toh U, Iwakuma N, Saku S, Akashi M, Kimitsuki Y, Seki N, Kawahara A, Ogo E, Itoh K, Akagi Y. Predictive factors of the tumor immunological microenvironment for long-term follow-up in early stage breast cancer. Cancer Sci 2017;108:81-90. [PMID: 27801993 DOI: 10.1111/cas.13114] [Cited by in Crossref: 31] [Cited by in F6Publishing: 35] [Article Influence: 5.2] [Reference Citation Analysis]
110 Marrone KA, Brahmer JR. Immune Checkpoint Therapy in Non-Small Cell Lung Cancer. Cancer J 2016;22:81-91. [PMID: 27111902 DOI: 10.1097/PPO.0000000000000178] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
111 Rodríguez-Otero P, Paiva B, Engelhardt M, Prósper F, San Miguel JF. Is immunotherapy here to stay in multiple myeloma? Haematologica 2017;102:423-32. [PMID: 28082344 DOI: 10.3324/haematol.2016.152504] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 4.7] [Reference Citation Analysis]
112 Marshall R, Popple A, Kordbacheh T, Honeychurch J, Faivre-Finn C, Illidge T. Immune Checkpoint Inhibitors in Lung Cancer - An Unheralded Opportunity? Clin Oncol (R Coll Radiol) 2017;29:207-17. [PMID: 28063623 DOI: 10.1016/j.clon.2016.12.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
113 Ogunleye F, Blankenship L, Millisor V, Anderson J, Jaiyesimi I. Programmed cell death-1/Programmed cell death ligand-1(PD-1/PD-L1) inhibitors, heralding a new era of immunotherapy in the management of advanced Non-Small Cell Lung Cancer (NSCLC). Cancer Treatment and Research Communications 2017;12:6-13. [DOI: 10.1016/j.ctarc.2017.05.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
114 Medina PJ, Adams VR. PD-1 Pathway Inhibitors: Immuno-Oncology Agents for Restoring Antitumor Immune Responses. Pharmacotherapy 2016;36:317-34. [PMID: 26822752 DOI: 10.1002/phar.1714] [Cited by in Crossref: 58] [Cited by in F6Publishing: 61] [Article Influence: 8.3] [Reference Citation Analysis]
115 Haghshenas MR, Dabbaghmanesh MH, Miri A, Ghaderi A, Erfani N. Association of PDCD1 gene markers with susceptibility to thyroid cancer. J Endocrinol Invest 2017;40:481-6. [DOI: 10.1007/s40618-016-0579-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
116 Kim S, Koh J, Kim M, Kwon D, Go H, Kim YA, Jeon YK, Chung DH. PD-L1 expression is associated with epithelial-to-mesenchymal transition in adenocarcinoma of the lung. Human Pathology 2016;58:7-14. [DOI: 10.1016/j.humpath.2016.07.007] [Cited by in Crossref: 95] [Cited by in F6Publishing: 90] [Article Influence: 13.6] [Reference Citation Analysis]
117 Zhang D, Chen Z, Wang DC, Wang X. Regulatory T cells and potential inmmunotherapeutic targets in lung cancer. Cancer Metastasis Rev 2015;34:277-90. [PMID: 25962964 DOI: 10.1007/s10555-015-9566-0] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.7] [Reference Citation Analysis]
118 Zarogoulidis K, Porpodis K, Domvri K, Eleftheriadou E, Ioannidou D, Zarogoulidis P. Diagnosing and treating pancoast tumors. Expert Rev Respir Med 2016;10:1255-8. [PMID: 27786592 DOI: 10.1080/17476348.2017.1246964] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
119 Fan Y, Ma K, Wang C, Ning J, Hu Y, Dong D, Dong X, Geng Q, Li E, Wu Y. Prognostic value of PD-L1 and PD-1 expression in pulmonary neuroendocrine tumors. Onco Targets Ther. 2016;9:6075-6082. [PMID: 27785054 DOI: 10.2147/ott.s115054] [Cited by in Crossref: 39] [Cited by in F6Publishing: 42] [Article Influence: 5.6] [Reference Citation Analysis]
120 Park BV, Freeman ZT, Ghasemzadeh A, Chattergoon MA, Rutebemberwa A, Steigner J, Winter ME, Huynh TV, Sebald SM, Lee SJ, Pan F, Pardoll DM, Cox AL. TGFβ1-Mediated SMAD3 Enhances PD-1 Expression on Antigen-Specific T Cells in Cancer. Cancer Discov 2016;6:1366-81. [PMID: 27683557 DOI: 10.1158/2159-8290.CD-15-1347] [Cited by in Crossref: 147] [Cited by in F6Publishing: 156] [Article Influence: 21.0] [Reference Citation Analysis]
121 Hu CY, Zhang YH, Wang T, Chen L, Gong ZH, Wan YS, Li QJ, Li YS, Zhu B. Interleukin-2 reverses CD8(+) T cell exhaustion in clinical malignant pleural effusion of lung cancer. Clin Exp Immunol 2016;186:106-14. [PMID: 27447482 DOI: 10.1111/cei.12845] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
122 Khanna S, Thomas A, Abate-Daga D, Zhang J, Morrow B, Steinberg SM, Orlandi A, Ferroni P, Schlom J, Guadagni F, Hassan R. Malignant Mesothelioma Effusions Are Infiltrated by CD3+ T Cells Highly Expressing PD-L1 and the PD-L1+ Tumor Cells within These Effusions Are Susceptible to ADCC by the Anti-PD-L1 Antibody Avelumab. J Thorac Oncol 2016;11:1993-2005. [PMID: 27544053 DOI: 10.1016/j.jtho.2016.07.033] [Cited by in Crossref: 81] [Cited by in F6Publishing: 88] [Article Influence: 11.6] [Reference Citation Analysis]
123 Yang J, Chen J, Wei J, Liu X, Cho WC. Immune checkpoint blockade as a potential therapeutic target in non-small cell lung cancer. Expert Opin Biol Ther 2016;16:1209-23. [PMID: 27426430 DOI: 10.1080/14712598.2016.1214265] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
124 Qin A, Coffey DG, Warren EH, Ramnath N. Mechanisms of immune evasion and current status of checkpoint inhibitors in non-small cell lung cancer. Cancer Med 2016;5:2567-78. [PMID: 27416962 DOI: 10.1002/cam4.819] [Cited by in Crossref: 45] [Cited by in F6Publishing: 48] [Article Influence: 6.4] [Reference Citation Analysis]
125 Han JJ, Kim D, Koh J, Keam B, Kim TM, Jeon YK, Lee S, Chung DH, Heo DS. Change in PD-L1 Expression After Acquiring Resistance to Gefitinib in EGFR-Mutant Non–Small-Cell Lung Cancer. Clinical Lung Cancer 2016;17:263-270.e2. [DOI: 10.1016/j.cllc.2015.11.006] [Cited by in Crossref: 71] [Cited by in F6Publishing: 92] [Article Influence: 10.1] [Reference Citation Analysis]
126 Sui X, Ma J, Han W, Wang X, Fang Y, Li D, Pan H, Zhang L. The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients. Oncotarget 2015;6:19393-404. [PMID: 26305724 DOI: 10.18632/oncotarget.5107] [Cited by in Crossref: 48] [Cited by in F6Publishing: 55] [Article Influence: 6.9] [Reference Citation Analysis]
127 Shien K, Papadimitrakopoulou VA, Wistuba II. Predictive biomarkers of response to PD-1/PD-L1 immune checkpoint inhibitors in non-small cell lung cancer. Lung Cancer 2016;99:79-87. [PMID: 27565919 DOI: 10.1016/j.lungcan.2016.06.016] [Cited by in Crossref: 82] [Cited by in F6Publishing: 91] [Article Influence: 11.7] [Reference Citation Analysis]
128 Bröckelmann PJ, Borchmann P, Engert A. Current and future immunotherapeutic approaches in Hodgkin lymphoma. Leuk Lymphoma 2016;57:2014-24. [PMID: 27243940 DOI: 10.1080/10428194.2016.1185789] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
129 Carbone DP, Gandara DR, Antonia SJ, Zielinski C, Paz-Ares L. Non-Small-Cell Lung Cancer: Role of the Immune System and Potential for Immunotherapy. J Thorac Oncol 2015;10:974-84. [PMID: 26134219 DOI: 10.1097/JTO.0000000000000551] [Cited by in Crossref: 89] [Cited by in F6Publishing: 96] [Article Influence: 12.7] [Reference Citation Analysis]
130 Duchnowska R, Pęksa R, Radecka B, Mandat T, Trojanowski T, Jarosz B, Czartoryska-Arłukowicz B, Olszewski WP, Och W, Kalinka-Warzocha E, Kozłowski W, Kowalczyk A, Loi S, Biernat W, Jassem J; Polish Brain Metastasis Consortium. Immune response in breast cancer brain metastases and their microenvironment: the role of the PD-1/PD-L axis. Breast Cancer Res 2016;18:43. [PMID: 27117582 DOI: 10.1186/s13058-016-0702-8] [Cited by in Crossref: 65] [Cited by in F6Publishing: 72] [Article Influence: 9.3] [Reference Citation Analysis]
131 Ameratunga M, Asadi K, Lin X, Walkiewicz M, Murone C, Knight S, Mitchell P, Boutros P, John T. PD-L1 and Tumor Infiltrating Lymphocytes as Prognostic Markers in Resected NSCLC. PLoS One 2016;11:e0153954. [PMID: 27104612 DOI: 10.1371/journal.pone.0153954] [Cited by in Crossref: 46] [Cited by in F6Publishing: 60] [Article Influence: 6.6] [Reference Citation Analysis]
132 Lowther DE, Goods BA, Lucca LE, Lerner BA, Raddassi K, van Dijk D, Hernandez AL, Duan X, Gunel M, Coric V, Krishnaswamy S, Love JC, Hafler DA. PD-1 marks dysfunctional regulatory T cells in malignant gliomas. JCI Insight 2016;1:e85935. [PMID: 27182555 DOI: 10.1172/jci.insight.85935] [Cited by in Crossref: 135] [Cited by in F6Publishing: 148] [Article Influence: 19.3] [Reference Citation Analysis]
133 Ji M, Liu Y, Li Q, Li X, Ning Z, Zhao W, Shi H, Jiang J, Wu C. PD-1/PD-L1 expression in non-small-cell lung cancer and its correlation with EGFR/KRAS mutations. Cancer Biol Ther 2016;17:407-13. [PMID: 26954523 DOI: 10.1080/15384047.2016.1156256] [Cited by in Crossref: 73] [Cited by in F6Publishing: 73] [Article Influence: 10.4] [Reference Citation Analysis]
134 Rossi E, Sgambato A, De Chiara G, Casaluce F, Losanno T, Sacco PC, Santabarbara G, Gridelli C. Endocrinopathies induced by immune-checkpoint inhibitors in advanced non-small cell lung cancer. Expert Rev Clin Pharmacol 2016;9:419-28. [PMID: 26681547 DOI: 10.1586/17512433.2016.1133289] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 2.9] [Reference Citation Analysis]
135 Jing W, Li M, Zhang Y, Teng F, Han A, Kong L, Zhu H. PD-1/PD-L1 blockades in non-small-cell lung cancer therapy. Onco Targets Ther 2016;9:489-502. [PMID: 26889087 DOI: 10.2147/OTT.S94993] [Cited by in Crossref: 34] [Cited by in F6Publishing: 41] [Article Influence: 4.9] [Reference Citation Analysis]
136 Tokito T, Azuma K, Kawahara A, Ishii H, Yamada K, Matsuo N, Kinoshita T, Mizukami N, Ono H, Kage M, Hoshino T. Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy. Eur J Cancer 2016;55:7-14. [PMID: 26771872 DOI: 10.1016/j.ejca.2015.11.020] [Cited by in Crossref: 128] [Cited by in F6Publishing: 142] [Article Influence: 18.3] [Reference Citation Analysis]
137 Mittal V, El Rayes T, Narula N, McGraw TE, Altorki NK, Barcellos-Hoff MH. The Microenvironment of Lung Cancer and Therapeutic Implications. Adv Exp Med Biol 2016;890:75-110. [PMID: 26703800 DOI: 10.1007/978-3-319-24932-2_5] [Cited by in Crossref: 67] [Cited by in F6Publishing: 71] [Article Influence: 9.6] [Reference Citation Analysis]
138 Lievense L, Aerts J, Hegmans J. Immune Therapy. Adv Exp Med Biol 2016;893:59-90. [PMID: 26667339 DOI: 10.1007/978-3-319-24223-1_4] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
139 Calles A, Liao X, Sholl LM, Rodig SJ, Freeman GJ, Butaney M, Lydon C, Dahlberg SE, Hodi F, Oxnard GR, Jackman DM, Jänne PA. Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer. Journal of Thoracic Oncology 2015;10:1726-35. [DOI: 10.1097/jto.0000000000000687] [Cited by in Crossref: 149] [Cited by in F6Publishing: 170] [Article Influence: 18.6] [Reference Citation Analysis]
140 Cortez MA, Ivan C, Valdecanas D, Wang X, Peltier HJ, Ye Y, Araujo L, Carbone DP, Shilo K, Giri DK, Kelnar K, Martin D, Komaki R, Gomez DR, Krishnan S, Calin GA, Bader AG, Welsh JW. PDL1 Regulation by p53 via miR-34. J Natl Cancer Inst. 2016;108. [PMID: 26577528 DOI: 10.1093/jnci/djv303] [Cited by in Crossref: 313] [Cited by in F6Publishing: 380] [Article Influence: 39.1] [Reference Citation Analysis]
141 Mayor M, Yang N, Sterman D, Jones DR, Adusumilli PS. Immunotherapy for non-small cell lung cancer: current concepts and clinical trials. Eur J Cardiothorac Surg 2016;49:1324-33. [PMID: 26516195 DOI: 10.1093/ejcts/ezv371] [Cited by in Crossref: 21] [Cited by in F6Publishing: 26] [Article Influence: 2.6] [Reference Citation Analysis]
142 Zheng P, Zhou Z. Human Cancer Immunotherapy with PD-1/PD-L1 Blockade. Biomark Cancer 2015;7:15-8. [PMID: 26448693 DOI: 10.4137/BIC.S29325] [Cited by in Crossref: 15] [Cited by in F6Publishing: 35] [Article Influence: 1.9] [Reference Citation Analysis]
143 Improta G, Leone I, Donia M, Gieri S, Pelosi G, Fraggetta F. New developments in the management of advanced melanoma - role of pembrolizumab. Onco Targets Ther 2015;8:2535-43. [PMID: 26396529 DOI: 10.2147/OTT.S72823] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
144 Natarajan A, Mayer AT, Xu L, Reeves RE, Gano J, Gambhir SS. Novel Radiotracer for ImmunoPET Imaging of PD-1 Checkpoint Expression on Tumor Infiltrating Lymphocytes. Bioconjug Chem 2015;26:2062-9. [PMID: 26307602 DOI: 10.1021/acs.bioconjchem.5b00318] [Cited by in Crossref: 107] [Cited by in F6Publishing: 118] [Article Influence: 13.4] [Reference Citation Analysis]
145 Lin C, Chen X, Li M, Liu J, Qi X, Yang W, Zhang H, Cai Z, Dai Y, Ouyang X. Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma. Clinical Lung Cancer 2015;16:e25-35. [DOI: 10.1016/j.cllc.2015.02.002] [Cited by in Crossref: 68] [Cited by in F6Publishing: 82] [Article Influence: 8.5] [Reference Citation Analysis]
146 Moon EK, Ranganathan R, Eruslanov E, Kim S, Newick K, O'Brien S, Lo A, Liu X, Zhao Y, Albelda SM. Blockade of Programmed Death 1 Augments the Ability of Human T Cells Engineered to Target NY-ESO-1 to Control Tumor Growth after Adoptive Transfer. Clin Cancer Res 2016;22:436-47. [PMID: 26324743 DOI: 10.1158/1078-0432.CCR-15-1070] [Cited by in Crossref: 85] [Cited by in F6Publishing: 89] [Article Influence: 10.6] [Reference Citation Analysis]
147 Kim S, Kim MY, Koh J, Go H, Lee DS, Jeon YK, Chung DH. Programmed death-1 ligand 1 and 2 are highly expressed in pleomorphic carcinomas of the lung: Comparison of sarcomatous and carcinomatous areas. Eur J Cancer. 2015;51:2698-2707. [PMID: 26329973 DOI: 10.1016/j.ejca.2015.08.013] [Cited by in Crossref: 115] [Cited by in F6Publishing: 127] [Article Influence: 14.4] [Reference Citation Analysis]
148 He J, Hu Y, Hu M, Li B. Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer. Sci Rep 2015;5:13110. [PMID: 26279307 DOI: 10.1038/srep13110] [Cited by in Crossref: 239] [Cited by in F6Publishing: 268] [Article Influence: 29.9] [Reference Citation Analysis]
149 Cooper WA, Tran T, Vilain RE, Madore J, Selinger CI, Kohonen-corish M, Yip P, Yu B, O’toole SA, Mccaughan BC, Yearley JH, Horvath LG, Kao S, Boyer M, Scolyer RA. PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma. Lung Cancer 2015;89:181-8. [DOI: 10.1016/j.lungcan.2015.05.007] [Cited by in Crossref: 187] [Cited by in F6Publishing: 214] [Article Influence: 23.4] [Reference Citation Analysis]
150 Koh J, Go H, Keam B, Kim MY, Nam SJ, Kim TM, Lee SH, Min HS, Kim YT, Kim DW, Jeon YK, Chung DH. Clinicopathologic analysis of programmed cell death-1 and programmed cell death-ligand 1 and 2 expressions in pulmonary adenocarcinoma: comparison with histology and driver oncogenic alteration status. Mod Pathol 2015;28:1154-66. [PMID: 26183759 DOI: 10.1038/modpathol.2015.63] [Cited by in Crossref: 114] [Cited by in F6Publishing: 125] [Article Influence: 14.3] [Reference Citation Analysis]
151 Görgün G, Samur MK, Cowens KB, Paula S, Bianchi G, Anderson JE, White RE, Singh A, Ohguchi H, Suzuki R, Kikuchi S, Harada T, Hideshima T, Tai YT, Laubach JP, Raje N, Magrangeas F, Minvielle S, Avet-Loiseau H, Munshi NC, Dorfman DM, Richardson PG, Anderson KC. Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma. Clin Cancer Res 2015;21:4607-18. [PMID: 25979485 DOI: 10.1158/1078-0432.CCR-15-0200] [Cited by in Crossref: 211] [Cited by in F6Publishing: 228] [Article Influence: 26.4] [Reference Citation Analysis]
152 Scagliotti GV, Bironzo P, Vansteenkiste JF. Addressing the unmet need in lung cancer: The potential of immuno-oncology. Cancer Treat Rev 2015;41:465-75. [PMID: 25936526 DOI: 10.1016/j.ctrv.2015.04.001] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 3.0] [Reference Citation Analysis]
153 Jones E, Mikropoulos C, Ahmed M. The future of immunotherapy in the treatment of lung cancer. Lung Cancer Management 2015;4:57-73. [DOI: 10.2217/lmt.15.2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
154 Butts CA. Anti-tumor immune response in early stage non small cell lung cancer (NSCLC): implications for adjuvant therapy. Transl Lung Cancer Res 2013;2:415-22. [PMID: 25806261 DOI: 10.3978/j.issn.2218-6751.2013.10.09] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
155 Pauken KE, Wherry EJ. Overcoming T cell exhaustion in infection and cancer. Trends Immunol. 2015;36:265-276. [PMID: 25797516 DOI: 10.1016/j.it.2015.02.008] [Cited by in Crossref: 638] [Cited by in F6Publishing: 667] [Article Influence: 79.8] [Reference Citation Analysis]
156 Swaika A, Hammond WA, Joseph RW. Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy. Mol Immunol 2015;67:4-17. [PMID: 25749122 DOI: 10.1016/j.molimm.2015.02.009] [Cited by in Crossref: 144] [Cited by in F6Publishing: 157] [Article Influence: 18.0] [Reference Citation Analysis]
157 Severson JJ, Serracino HS, Mateescu V, Raeburn CD, McIntyre RC, Sams SB, Haugen BR, French JD. PD-1+Tim-3+ CD8+ T Lymphocytes Display Varied Degrees of Functional Exhaustion in Patients with Regionally Metastatic Differentiated Thyroid Cancer. Cancer Immunol Res. 2015;3:620-630. [PMID: 25701326 DOI: 10.1158/2326-6066.cir-14-0201] [Cited by in Crossref: 51] [Cited by in F6Publishing: 57] [Article Influence: 6.4] [Reference Citation Analysis]
158 Linch SN, McNamara MJ, Redmond WL. OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal. Front Oncol. 2015;5:34. [PMID: 25763356 DOI: 10.3389/fonc.2015.00034] [Cited by in Crossref: 159] [Cited by in F6Publishing: 169] [Article Influence: 19.9] [Reference Citation Analysis]
159 Qian N, Gao L, Dong L, Liu H, Fu J, Meng D, Gao X, Zhang J, Gao Y, Song H. Construction, expression, purification, and characterization of a dual-targeting PD-1/VEGF-A fusion protein (P-V). Protein Expr Purif 2015;109:1-6. [PMID: 25616235 DOI: 10.1016/j.pep.2015.01.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
160 Bellmunt J, Mullane SA, Werner L, Fay AP, Callea M, Leow JJ, Taplin ME, Choueiri TK, Hodi FS, Freeman GJ, Signoretti S. Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma. Ann Oncol 2015;26:812-7. [PMID: 25600565 DOI: 10.1093/annonc/mdv009] [Cited by in Crossref: 200] [Cited by in F6Publishing: 217] [Article Influence: 25.0] [Reference Citation Analysis]
161 Ji M, Liu Y, Li Q, Li XD, Zhao WQ, Zhang H, Zhang X, Jiang JT, Wu CP. PD-1/PD-L1 pathway in non-small-cell lung cancer and its relation with EGFR mutation. J Transl Med 2015;13:5. [PMID: 25592115 DOI: 10.1186/s12967-014-0373-0] [Cited by in Crossref: 49] [Cited by in F6Publishing: 56] [Article Influence: 6.1] [Reference Citation Analysis]
162 Prado-garcia H, Romero-garcia S, Lopez-gonzalez JS. The Role of Exhaustion in Tumor-Induced T Cell Dysfunction in Cancer. Cancer Immunology 2015. [DOI: 10.1007/978-3-662-44006-3_5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
163 Clifton GT, Mittendorf EA, Peoples GE. Overcoming Cancer Tolerance with Immune Checkpoint Blockade. Cancer Immunology 2015. [DOI: 10.1007/978-3-662-44946-2_6] [Reference Citation Analysis]
164 Kadara H, Franklin WA, Wistuba II. Inflammation and Lung Cancer: Molecular Pathology. Inflammation and Lung Cancer 2015. [DOI: 10.1007/978-1-4939-2724-1_3] [Reference Citation Analysis]
165 Tsang KY, Jochems C, Schlom J. Insights on Peptide Vaccines in Cancer Immunotherapy. Cancer Drug Discovery and Development 2015. [DOI: 10.1007/978-3-319-21167-1_1] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
166 Rekik R, Belhadj Hmida N, Ben Hmid A, Zamali I, Kammoun N, Ben Ahmed M. PD-1 induction through TCR activation is partially regulated by endogenous TGF-β. Cell Mol Immunol 2015;12:648-9. [PMID: 25363526 DOI: 10.1038/cmi.2014.104] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 2.7] [Reference Citation Analysis]
167 Ohaegbulam KC, Assal A, Lazar-Molnar E, Yao Y, Zang X. Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends Mol Med. 2015;21:24-33. [PMID: 25440090 DOI: 10.1016/j.molmed.2014.10.009] [Cited by in Crossref: 409] [Cited by in F6Publishing: 453] [Article Influence: 45.4] [Reference Citation Analysis]
168 Chen L, Gibbons DL, Goswami S, Cortez MA, Ahn YH, Byers LA, Zhang X, Yi X, Dwyer D, Lin W. Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. Nat Commun. 2014;5:5241. [PMID: 25348003 DOI: 10.1038/ncomms6241] [Cited by in Crossref: 569] [Cited by in F6Publishing: 626] [Article Influence: 63.2] [Reference Citation Analysis]
169 Waki K, Yamada T, Yoshiyama K, Terazaki Y, Sakamoto S, Matsueda S, Komatsu N, Sugawara S, Takamori S, Itoh K, Yamada A. PD-1 expression on peripheral blood T-cell subsets correlates with prognosis in non-small cell lung cancer. Cancer Sci 2014;105:1229-35. [PMID: 25117757 DOI: 10.1111/cas.12502] [Cited by in Crossref: 50] [Cited by in F6Publishing: 55] [Article Influence: 5.6] [Reference Citation Analysis]
170 Carnio S, Novello S, Bironzo P, Scagliotti GV. Moving from histological subtyping to molecular characterization: new treatment opportunities in advanced non-small-cell lung cancer. Expert Rev Anticancer Ther 2014;14:1495-513. [PMID: 25183305 DOI: 10.1586/14737140.2014.949245] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
171 Vanderstraeten A, Luyten C, Verbist G, Tuyaerts S, Amant F. Mapping the immunosuppressive environment in uterine tumors: implications for immunotherapy. Cancer Immunol Immunother 2014;63:545-57. [PMID: 24658839 DOI: 10.1007/s00262-014-1537-8] [Cited by in Crossref: 80] [Cited by in F6Publishing: 75] [Article Influence: 8.9] [Reference Citation Analysis]
172 Zeng W, Wang Y, Liu Z, Khanniche A, Hu Q, Feng Y, Ye W, Yang J, Wang S, Zhou L, Shen H, Wang Y. Long-term exposure to decabrominated diphenyl ether impairs CD8 T-cell function in adult mice. Cell Mol Immunol 2014;11:367-76. [PMID: 24705197 DOI: 10.1038/cmi.2014.16] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
173 Yang L, Wu Y. Recent advances of immunotherapy in lung cancer: anti-programmed cell death-1/programmed death ligand-1 antibodies. Lung Cancer Management 2014;3:175-90. [DOI: 10.2217/lmt.13.80] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
174 Harvey RD. Immunologic and clinical effects of targeting PD-1 in lung cancer. Clin Pharmacol Ther. 2014;96:214-223. [PMID: 24690569 DOI: 10.1038/clpt.2014.74] [Cited by in Crossref: 56] [Cited by in F6Publishing: 65] [Article Influence: 6.2] [Reference Citation Analysis]
175 Xu Y, Wang M. [Progress in immunotherapy for non-small cell lung cancer]. Zhongguo Fei Ai Za Zhi 2014;17:34-41. [PMID: 24398312 DOI: 10.3779/j.issn.1009-3419.2014.01.06] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
176 Creelan BC. Update on Immune Checkpoint Inhibitors in Lung Cancer. Cancer Control 2014;21:80-9. [DOI: 10.1177/107327481402100112] [Cited by in Crossref: 61] [Cited by in F6Publishing: 71] [Article Influence: 6.8] [Reference Citation Analysis]
177 Reungwetwattana T, Dy GK. Targeted therapies in development for non-small cell lung cancer. J Carcinog 2013;12:22. [PMID: 24574860 DOI: 10.4103/1477-3163.123972] [Cited by in Crossref: 47] [Cited by in F6Publishing: 54] [Article Influence: 4.7] [Reference Citation Analysis]
178 Sznol M, Chen L. Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer. Clin Cancer Res 2013;19:1021-34. [PMID: 23460533 DOI: 10.1158/1078-0432.CCR-12-2063] [Cited by in Crossref: 364] [Cited by in F6Publishing: 401] [Article Influence: 36.4] [Reference Citation Analysis]
179 Atanackovic D, Luetkens T, Kröger N. Coinhibitory molecule PD-1 as a potential target for the immunotherapy of multiple myeloma. Leukemia 2014;28:993-1000. [DOI: 10.1038/leu.2013.310] [Cited by in Crossref: 68] [Cited by in F6Publishing: 76] [Article Influence: 6.8] [Reference Citation Analysis]
180 Tartour E, Zitvogel L. Lung cancer: potential targets for immunotherapy. Lancet Respir Med 2013;1:551-63. [PMID: 24461616 DOI: 10.1016/S2213-2600(13)70159-0] [Cited by in Crossref: 51] [Cited by in F6Publishing: 58] [Article Influence: 5.1] [Reference Citation Analysis]
181 Rangachari D, Brahmer JR. Targeting the Immune System in the Treatment of Non-Small-Cell Lung Cancer. Curr Treat Options in Oncol 2013;14:580-94. [DOI: 10.1007/s11864-013-0250-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
182 McDermott DF, Atkins MB. PD-1 as a potential target in cancer therapy. Cancer Med 2013;2:662-73. [PMID: 24403232 DOI: 10.1002/cam4.106] [Cited by in Crossref: 257] [Cited by in F6Publishing: 319] [Article Influence: 25.7] [Reference Citation Analysis]
183 McCarthy F, Roshani R, Steele J, Hagemann T. Current clinical immunotherapy targets in advanced nonsmall cell lung cancer (NSCLC). J Leukoc Biol 2013;94:1201-6. [PMID: 23695306 DOI: 10.1189/jlb.0313121] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
184 Chow LQ. Exploring Novel Immune-Related Toxicities and Endpoints with Immune-Checkpoint Inhibitors in Non-Small Cell Lung Cancer. American Society of Clinical Oncology Educational Book 2013. [DOI: 10.14694/edbook_am.2013.33.e280] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
185 Hamid O, Carvajal RD. Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy. Expert Opinion on Biological Therapy 2013;13:847-61. [DOI: 10.1517/14712598.2013.770836] [Cited by in Crossref: 89] [Cited by in F6Publishing: 98] [Article Influence: 8.9] [Reference Citation Analysis]
186 Prado-Garcia H, Romero-Garcia S, Aguilar-Cazares D, Meneses-Flores M, Lopez-Gonzalez JS. Tumor-induced CD8+ T-cell dysfunction in lung cancer patients. Clin Dev Immunol 2012;2012:741741. [PMID: 23118782 DOI: 10.1155/2012/741741] [Cited by in Crossref: 53] [Cited by in F6Publishing: 56] [Article Influence: 4.8] [Reference Citation Analysis]
187 Reck M. What future opportunities may immuno-oncology provide for improving the treatment of patients with lung cancer? Annals of Oncology 2012;23:viii28-34. [DOI: 10.1093/annonc/mds260] [Cited by in Crossref: 35] [Cited by in F6Publishing: 39] [Article Influence: 3.2] [Reference Citation Analysis]
188 Peng W, Liu C, Xu C, Lou Y, Chen J, Yang Y, Yagita H, Overwijk WW, Lizée G, Radvanyi L, Hwu P. PD-1 blockade enhances T-cell migration to tumors by elevating IFN-γ inducible chemokines. Cancer Res 2012;72:5209-18. [PMID: 22915761 DOI: 10.1158/0008-5472.CAN-12-1187] [Cited by in Crossref: 276] [Cited by in F6Publishing: 295] [Article Influence: 25.1] [Reference Citation Analysis]
189 French JD, Kotnis GR, Said S, Raeburn CD, McIntyre RC Jr, Klopper JP, Haugen BR. Programmed death-1+ T cells and regulatory T cells are enriched in tumor-involved lymph nodes and associated with aggressive features in papillary thyroid cancer. J Clin Endocrinol Metab 2012;97:E934-43. [PMID: 22466343 DOI: 10.1210/jc.2011-3428] [Cited by in Crossref: 69] [Cited by in F6Publishing: 76] [Article Influence: 6.3] [Reference Citation Analysis]
190 Schneider T, Hoffmann H, Dienemann H, Schnabel PA, Enk AH, Ring S, Mahnke K. Non-small cell lung cancer induces an immunosuppressive phenotype of dendritic cells in tumor microenvironment by upregulating B7-H3. J Thorac Oncol 2011;6:1162-8. [PMID: 21597388 DOI: 10.1097/JTO.0b013e31821c421d] [Cited by in Crossref: 57] [Cited by in F6Publishing: 67] [Article Influence: 4.8] [Reference Citation Analysis]
191 Sterlacci W, Wolf D, Savic S, Hilbe W, Schmid T, Jamnig H, Fiegl M, Tzankov A. High transforming growth factor β expression represents an important prognostic parameter for surgically resected non-small cell lung cancer. Hum Pathol 2012;43:339-49. [PMID: 21840566 DOI: 10.1016/j.humpath.2011.05.017] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 2.8] [Reference Citation Analysis]
192 Watkins SK, Zhu Z, Riboldi E, Shafer-Weaver KA, Stagliano KE, Sklavos MM, Ambs S, Yagita H, Hurwitz AA. FOXO3 programs tumor-associated DCs to become tolerogenic in human and murine prostate cancer. J Clin Invest 2011;121:1361-72. [PMID: 21436588 DOI: 10.1172/JCI44325] [Cited by in Crossref: 103] [Cited by in F6Publishing: 114] [Article Influence: 8.6] [Reference Citation Analysis]
193 Wang SF, Fouquet S, Chapon M, Salmon H, Regnier F, Labroquère K, Badoual C, Damotte D, Validire P, Maubec E, Delongchamps NB, Cazes A, Gibault L, Garcette M, Dieu-Nosjean MC, Zerbib M, Avril MF, Prévost-Blondel A, Randriamampita C, Trautmann A, Bercovici N. Early T cell signalling is reversibly altered in PD-1+ T lymphocytes infiltrating human tumors. PLoS One 2011;6:e17621. [PMID: 21408177 DOI: 10.1371/journal.pone.0017621] [Cited by in Crossref: 74] [Cited by in F6Publishing: 76] [Article Influence: 6.2] [Reference Citation Analysis]
194 Du C, Wang Y. The immunoregulatory mechanisms of carcinoma for its survival and development. J Exp Clin Cancer Res 2011;30:12. [PMID: 21255410 DOI: 10.1186/1756-9966-30-12] [Cited by in Crossref: 40] [Cited by in F6Publishing: 44] [Article Influence: 3.3] [Reference Citation Analysis]
195 Melenhorst JJ, Barrett AJ. Tumor vaccines and beyond. Cytotherapy 2011;13:8-18. [PMID: 21067312 DOI: 10.3109/14653249.2010.530649] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
196 Plate JM, Jo Fidler M. Research Highlights: Immunotherapy to overcome lung tumor cell-induced escape from immunosurveillance. Immunotherapy 2010;2:757-60. [DOI: 10.2217/imt.10.62] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]